Laura Elisa Villegas Sierra

Laura Elisa Villegas Sierra

Auto-generated profile, based on publicly available information

Laura Elisa Villegas Sierra

Medizinische Klinik und Poliklinik I, University Hospital Munich, Ludwig-Maximilians University, Germany (L.F., P.S., L.S., A.K., M.W., L.T., L.E.V.S., M.F.V., L.E.S., A.-K.M., E.E., A.S., M.K., S.M., K.D.R.).

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in Circulation
Verified
Journal Article
Closed access
ELEnzo Lüsebrink
Enzo Lüsebrink
LBLeonhard Binzenhöfer
Leonhard Binzenhöfer
DHDaniel Hering
Daniel Hering
LSLaura Villegas Sierra
Laura Villegas Sierra
BSBenedikt Schrage
Benedikt Schrage
HTHolger Thiele
Holger Thiele
The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for temporary mechanical circulatory support in various clinical scenarios has been increasing consistently, despite the lack of sufficient evidence regarding its benefit and safety from adequately powered randomized controlled trials. Although the ARREST trial (Advanced Reperfusion Strategies for Patients with Out-of-Hospital Cardiac Arrest and Refractory Ventricular Fibrillation) and a secondary analysis of the PRAGUE OHCA trial (Prague Out-of-Hospital Cardiac Arrest) provided some evidence in favor of VA-ECMO in the setting of out-of-hospital cardiac arrest, the INCEPTION trial (Early Initiation of Extracorporeal Life Support in Refractory Out-of-Hospital Cardiac Arrest) has not found a relevant improvement of short-term mortality with extracorporeal cardiopulmonary resuscitation. In addition, the results of the recently published ECLS-SHOCK trial (Extracorporeal Life Support in Cardiogenic Shock) and ECMO-CS trial (Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock) discourage the routine use of VA-ECMO in patients with infarct-related cardiogenic shock. Ongoing clinical trials (ANCHOR [Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock, NCT04184635], REVERSE [Impella CP With VA ECMO for Cardiogenic Shock, NCT03431467], UNLOAD ECMO [Left Ventricular Unloading to Improve Outcome in Cardiogenic Shock Patients on VA-ECMO, NCT05577195], PIONEER [Hemodynamic Support With ECMO and IABP in Elective Complex High-risk PCI, NCT04045873]) may clarify the usefulness of VA-ECMO in specific patient subpopulations and the efficacy of combined mechanical circulatory support strategies. Pending further data to refine patient selection and management recommendations for VA-ECMO, it remains uncertain whether the present usage of this device improves outcomes.

3 August 2023 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
BFBeatriz Elena Preciado Franco
Beatriz Elena Preciado Franco
DODiego Moran Ortiz
Diego Moran Ortiz
CLCamila Lema
Camila Lema
MTMaria Jose Fernandez Turizo
Maria Jose Fernandez Turizo
ECEsteban Calle Correa
Esteban Calle Correa
MLMauricio Lema
Mauricio Lema
Purpose: This is the first report of an institutional-based cancer registry in Clínica de Oncología Astorga, in Medellín, Colombia. It was created to produce local information on socio-demographic and clinical characteristics, therapies, and survival outcomes of patients with the most frequent tumors in the institution. Methods: All consecutive patients with cancers of the breast (BC), prostate (PC), lung (LC), colorectal (CRC), ovarian, stomach, pancreas, cervical, and melanoma, diagnosed after January 1/2019, and treated at the institution were included. A description of the entire cohort and of the five most frequent tumor types was performed. Kaplan-Meier curves for each tumor stage were used to estimate overall survival (OS) and progression-free survival (PFS). Statistical analysis was performed using SPSS v22. Results: Data from 729 patients were analyzed. The median follow-up was 12.0 months (IQR 5.8-18.1). The main diagnoses were BC, PC, CRC, LC, and cervical cancer in 57.2%, 10.2%, 8.0%, 7.7%, and 5.8% of patients, respectively. The most frequent stage at diagnosis was: stage II for BC (36.6%) and PC (35.1%), stage III for CRC (62.1%) and cervical cancer (50.0%), and stage IV for LC (62.5%). In BC cases, the median PFS for stage IV patients was 10.8 months (95%CI: 8.7-13.0). In LC cases, median PFS and OS for stage IV were 5.6 months (95%CI: 4.1-7.0), and 6.8 months (95%CI: 2.5-11.1), respectively. Conclusion: Even though follow-up is short in this first report, PFS for metastatic BC and PFS and OS for metastatic LC reflect the aggressive nature of these conditions in Colombia.

1 January 2025 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
LFLuisa Freyer
Luisa Freyer
PSPeter Spielbichler
Peter Spielbichler
LSLukas von Stülpnagel
Lukas von Stülpnagel
AKAresa Krasniqi
Aresa Krasniqi
MWMaximilian Wörndl
Maximilian Wörndl
KRKonstantinos D. Rizas
Konstantinos D. Rizas

28 June 2023 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
BPBeatriz Preciado
Beatriz Preciado
DMDiego Morán
Diego Morán
CLCamila Lema
Camila Lema
MFMaría José Fernández
María José Fernández
ECEsteban Calle
Esteban Calle
MLMauricio Lema
Mauricio Lema
Introducción: el conocimiento demográfico y de supervivencia del cáncer en Colombia es limitado, sin embargo, el intento de mejorar este registro está en aumento. La Clínica de Oncología Astorga es un centro de tercer nivel que brinda atención especializada en cáncer en Medellín, Colombia. En el año 2019 se creó un registro de cáncer institucional para describir las características sociodemográficas, clínicas, terapéuticas y los resultados de supervivencia de los diez tipos de tumores sólidos más frecuentes en la institución.